#114353
Re: Farmas USA
Health-care drama has now spread to biopharma stocks
The recent decline in health-care stocks comes during an uncertain time for the future of U.S. health-care policy, with lawmakers demanding tighter regulations and transparency on drug prices and questions swirling around the probability of the country implementing a single-payer system, also known as “Medicare for All.”
Investors initially seemed more concerned about the impact such a system could have on managed-care companies and insurers. But “sub-sectors are all naturally intertwined,” said Michael Yee of Jefferies in a note to clients on Thursday, calling the hit to biopharma “collateral damage.”
